PMID- 28677745
OWN - NLM
STAT- MEDLINE
DCOM- 20180510
LR  - 20220321
IS  - 1791-2423 (Electronic)
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 51
IP  - 3
DP  - 2017 Sep
TI  - Galectin-1 is a diagnostic marker involved in thyroid cancer progression.
PG  - 760-770
LID - 10.3892/ijo.2017.4065 [doi]
AB  - Fine-needle aspiration (FNA) is the most commonly used pre-operative technique 
      for diagnosis of malignant thyroid tumor. However, many benign lesions, with 
      indeterminate diagnosis following FNA, are referred to surgery. Based on 
      multifunctionality of the endogenous galectin-1, we aimed to assess its status 
      for early diagnosis of thyroid cancer. Immunohistochemistry for galectin-1 and -3 
      was performed on a clinical series of 69 cases of thyroid lesions. Galectin-1 
      expression was further examined in two additional tissue microarrays (TMA) 
      composed of 66 follicular adenomas and 66 papillary carcinomas in comparison to 
      galectin-3 and cytokeratin-19 (CK19). In addition, a knockdown of galectin-1 in 
      papillary (TPC-1) and anaplastic (8505C) thyroid cancer cell lines was achieved 
      by lentiviral transduction for in vitro experiments. A murine orthotopic thyroid 
      cancer model was used to investigate tumor growth and metastatic ability. 
      Immunohistochemical analyses of galectin-1 and -3 in the series of 69 cases of 
      thyroid lesions revealed that galectin-1 was completely absent in the epithelial 
      compartment of all benign thyroid lesions. Levels of both galectins significantly 
      increased in the cytoplasmic compartment of malignant thyroid cells. Galectin-1 
      expression in the TMA yielded an excellent specificity (97%), while galectin-3 
      and CK19 presented a higher sensitivity (>97%) in discriminating benign from 
      malignant thyroid lesions. In vitro experiments revealed that migration was 
      negatively affected in TPC-1 galectin-1 knockdown (KD) cells, and that 
      proliferation and invasion capacity of 8505C cells decreased after galectin-1 KD. 
      Moreover, an orthotopic mouse model displayed a lower rate of tumor development 
      with galectin-1 KD thyroid anaplastic cancer cells than in the control. Our 
      findings support the introduction of galectin-1 as a reliable diagnostic marker 
      for thyroid carcinomas. Its involvement in cell proliferation, migration, 
      invasion and tumor growth also intimate functional involvement of galectin-1 in 
      the progression of thyroid carcinoma, suggesting its potential as a therapeutic 
      target.
FAU - Arcolia, Vanessa
AU  - Arcolia V
AD  - Laboratory of Human Anatomy and Experimental Oncology, Faculty of Medicine and 
      Pharmacy, University of Mons, Mons, Belgium.
FAU - Journe, Fabrice
AU  - Journe F
AD  - Laboratory of Human Anatomy and Experimental Oncology, Faculty of Medicine and 
      Pharmacy, University of Mons, Mons, Belgium.
FAU - Wattier, Aurore
AU  - Wattier A
AD  - Laboratory of Human Anatomy and Experimental Oncology, Faculty of Medicine and 
      Pharmacy, University of Mons, Mons, Belgium.
FAU - Leteurtre, Emmanuelle
AU  - Leteurtre E
AD  - Universite Lille, Inserm, CHU Lille, UMR-S 1172 - JPARC - Jean-Pierre Aubert 
      Research Center, F-59000 Lille, France.
FAU - Renaud, Florence
AU  - Renaud F
AD  - Universite Lille, Inserm, CHU Lille, UMR-S 1172 - JPARC - Jean-Pierre Aubert 
      Research Center, F-59000 Lille, France.
FAU - Gabius, Hans-Joachim
AU  - Gabius HJ
AD  - Institute of Physiological Chemistry, Faculty of Veterinary Medicine, Ludwig 
      Maximilians University, D-80539 Munich, Germany.
FAU - Remmelink, Myriam
AU  - Remmelink M
AD  - Department of Pathology, Hospital Erasme, Universite Libre de Bruxelles, 
      Brussels, Belgium.
FAU - Decaestecker, Christine
AU  - Decaestecker C
AD  - Laboratory of Image, Signal Processing and Acoustics (LISA), Ecole Polytechnique 
      de Bruxelles, Universite Libre de Bruxelles, Brussels, Belgium.
FAU - Rodriguez, Alexandra
AU  - Rodriguez A
AD  - Department of Oto-Rhino-Laryngology, CHU Saint-Pierre, Universite Libre de 
      Bruxelles, Brussels, Belgium.
FAU - Boutry, Sebastien
AU  - Boutry S
AD  - Center for Microscopy and Molecular Imaging (CMMI), Gosselies, Belgium.
FAU - Laurent, Sophie
AU  - Laurent S
AD  - Center for Microscopy and Molecular Imaging (CMMI), Gosselies, Belgium.
FAU - Saussez, Sven
AU  - Saussez S
AD  - Laboratory of Human Anatomy and Experimental Oncology, Faculty of Medicine and 
      Pharmacy, University of Mons, Mons, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20170704
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Galectin 1)
RN  - 0 (Galectin 3)
RN  - 0 (Keratin-19)
SB  - IM
MH  - Adenoma/*diagnosis/genetics/pathology
MH  - Adult
MH  - Animals
MH  - Biomarkers, Tumor/genetics
MH  - Biopsy, Fine-Needle
MH  - Carcinoma, Papillary/*diagnosis/genetics/pathology
MH  - Cell Line, Tumor
MH  - Diagnosis, Differential
MH  - Disease Progression
MH  - Early Detection of Cancer
MH  - Female
MH  - Galectin 1/*genetics
MH  - Galectin 3/genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Keratin-19/genetics
MH  - Male
MH  - Mice
MH  - Middle Aged
MH  - Neoplasms/*diagnosis/genetics/pathology
MH  - Thyroid Cancer, Papillary
MH  - Thyroid Gland/pathology
MH  - Thyroid Neoplasms/*diagnosis/genetics/pathology
MH  - Xenograft Model Antitumor Assays
PMC - PMC5564411
EDAT- 2017/07/06 06:00
MHDA- 2018/05/11 06:00
PMCR- 2017/07/04
CRDT- 2017/07/06 06:00
PHST- 2017/01/24 00:00 [received]
PHST- 2017/04/27 00:00 [accepted]
PHST- 2017/07/06 06:00 [pubmed]
PHST- 2018/05/11 06:00 [medline]
PHST- 2017/07/06 06:00 [entrez]
PHST- 2017/07/04 00:00 [pmc-release]
AID - ijo-51-03-0760 [pii]
AID - 10.3892/ijo.2017.4065 [doi]
PST - ppublish
SO  - Int J Oncol. 2017 Sep;51(3):760-770. doi: 10.3892/ijo.2017.4065. Epub 2017 Jul 4.